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Background. Dengue endangers billions of people in the tropical world, yet no therapeutic is currently available. In part, the
severe manifestations of dengue reﬂect inﬂammatory processes affecting the vascular endothelium. In addition to lipid lowering,
statins have pleiotropic effects that improve endothelial function, and epidemiological studies suggest that outcomes from a range
of acute inﬂammatory syndromes are improved in patients already on statin therapy.
Methods. Following satisfactory review of a short pilot phase (40 mg lovastatin vs placebo in 30 cases), we performed a random-
ized, double-blind, placebo-controlled trial of 5 days of 80 mg lovastatin vs placebo in 300 Vietnamese adults with a positive dengue
NS1 rapid test presenting within 72 hours of fever onset. The primary outcome was safety. Secondary outcomes included compar-
isons of disease progression rates, fever clearance times, and measures of plasma viremia and quality of life between the treatment
arms.
Results. Adverse events occurred with similar frequency in both groups (97/151 [64%] placebo vs 82/149 [55%] lovastatin;
P = .13), and were in keeping with the characteristic clinical and laboratory features of acute dengue. We also observed no difference
in serious adverse events or any of the secondary outcome measures.
Conclusions. We found lovastatin to be safe and well tolerated in adults with dengue. However, although the study was not
powered to address efﬁcacy, we found no evidence of a beneﬁcial effect on any of the clinical manifestations or on dengue viremia.
Continuing established statin therapy in patients who develop dengue is safe.
Clinical Trials Registration. ISRCTN03147572.
Keywords. dengue; lovastatin; randomized clinical trial.
Dengue exerts an enormous toll on the tropical world, with ap-
proximately 390 million infections annually [1]. While most
patients recover after a short but often debilitating illness, a pro-
portion progress to severe disease, characterized by endothelial
dysfunction and plasma leakage that may result in hypovolemic
shock [2].Other potentially severe complications include bleed-
ing and liver/organ involvement [2]. Myalgia and arthralgia are
prominent symptoms associated with dengue, and rhabdomy-
olysis is also occasionally reported [3]. No vaccine or effective
therapeutic is available as yet, and health systems in endemic
areas are frequently overwhelmed with patients during the
dengue season [2]. There is a need for a therapeutic that can
shorten the duration and severity of symptoms.
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors, also known as statins, have beneﬁcial ef-
fects beyond their lipid-lowering properties, including effects
on endothelial function [4, 5]. These effects are mediated
through effects on the mevalonate pathway, resulting in reduced
expression of proinﬂammatory cytokines, thereby controlling
leukocyte migration to areas of endothelial inﬂammation [6].
Statins may improve endothelial function by modulating the
production of reactive oxygen species [7]. Endothelial dysfunc-
tion is recognized as an important factor in atherosclerosis
pathogenesis [8], and these effects, together with the lipid-
lowering properties, likely explain the beneﬁts of statin use in
cardiovascular disease. There is overlap between the inﬂam-
matory processes seen in atherosclerosis and sepsis, and obser-
vational studies have suggested that statin therapy may be
associated with improved outcomes in inﬂammatory conditions
[9–11]. Statins are being investigated as adjunctive therapy for a
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variety of conditions such as sepsis and acute respiratory dis-
tress syndrome in which endothelial dysfunction is thought to
play a role. To date their adjunctive role has not been substan-
tiated [12, 13].
Although the mechanisms underlying the endothelial dys-
function seen in severe dengue remain incompletely under-
stood, we hypothesized that the endothelial stabilizing effects
of statins could favorably modulate dengue vasculopathy. In ad-
dition, in vitro work has shown that lovastatin reduces dengue
virion assembly, raising the possibility that statins may have an-
tiviral properties [14–16]. Although statins have a good safety
proﬁle, given the recognized association between statin use and
hepatic and muscle dysfunction [17, 18], both well-recognized
features of dengue, our primary objective was to assess the safety
of lovastatin in dengue patients. In addition, we investigated the
effects of lovastatin on a variety of clinical and virological
parameters.
METHODS
Study Design and Participants
We performed a randomized, placebo-controlled, double-blind,
dose-escalating trial of lovastatin for adult dengue patients at 2
centers in Vietnam (Hospital for Tropical Diseases, Ho Chi
Minh City; Tien Giang Hospital, My Tho City) [19]. In phase
1, we assessed 40 mg lovastatin vs placebo in 30 patients, fol-
lowed, after satisfactory safety review, by 80 mg lovastatin vs
placebo in 300 patients in phase 2.
Ethical approval was obtained from the institutional review
boards (IRBs) of the Hospital for Tropical Diseases and the
Vietnam Ministry of Health, the London School of Hygiene
and Tropical Medicine, and the Oxford University Tropical Re-
search Ethics Committee. The trial was registered with the
ISRCTN registry (ISRCTN03147572).
The trial protocol has been published elsewhere [19]. In brief,
patients aged ≥18 years, presenting within 72 hours of fever
onset with an illness consistent with dengue, in whom a rapid
test for dengue nonstructural protein 1 (NS1) was positive (NS1
Ag-STRIP, Bio-Rad) were eligible for inclusion providing they
gave written informed consent. Exclusions included an alanine
aminotransferase (ALT) level >150 U/L, a creatine kinase (CK)
level >1000 U/L, a platelet count <50 cells × 109/L, pregnancy or
lactation, or a history of cirrhosis or myopathy. Patients were
excluded if they were currently taking statins or any medication
contraindicated with statins.
Randomization and Masking
We randomly assigned enrolled patients in a 1:1 ratio to receive
lovastatin or placebo once daily for 5 days. Randomization was
stratiﬁed by ward of recruitment, using block randomization
(block sizes of 4 or 6). The Vietnamese company DOMESCO
provided lovastatin and visually matched placebo without char-
ge. Only the clinical trials pharmacist had access to the
randomization list; she prepackaged bottles containing 6
doses of either lovastatin or visually matched placebo. All
other study staff were blinded to treatment allocation until
after completion of the study and database locking. Each en-
rolled patient was assigned the next available study code that
corresponded to a prepackaged bottle of study drug. Clinical
data were captured on structured case report forms that were
entered into a secure Web-based database.
Study Procedures
Participants were identiﬁed on the dengue wards and among
patients attending outpatients who agreed to be hospitalized.
Screening was streamlined to ensure completion within 4
hours. Participants received the ﬁrst dose of study drug as
soon as possible after randomization, with subsequent doses
given once daily in the morning. Standardized clinical informa-
tion was recorded daily throughout the disease course. Study
physicians were responsible for all clinical management deci-
sions with the following caveats: If the ALT level exceeded
250 U/L, the CK level exceeded 1000 U/L, or the platelet
count fell below 5 × 109/L, the study drug was stopped. Adverse
events (AEs) and details of severity and likely relatedness to
the study drug were recorded in the case report form. Serious
adverse events (SAEs) were reported to the relevant IRBs and
to an independent data and safety monitoring committee
(DSMB).
Hematocrit, platelet, and total cholesterol measurements
were performed at enrollment (study day 1), then daily to
study day 6, and at the follow-up visit 4 weeks after enrollment.
Renal and liver function tests, electrolytes, and coagulation pro-
ﬁles were carried out on study days 1, 3, 5, and at follow-up. A 2-
dimensional ultrasound scan was performed on illness day 6 to
quantify the presence of plasma leak. Quality of life was mea-
sured using a visual analogue scale daily.
Serological and virological tests were used to conﬁrm the
dengue diagnosis and identify the infecting serotype, as out-
lined in Supplementary Text 1. Viremia was quantiﬁed on the
daily plasma samples using a serotype-speciﬁc, real-time reverse
transcription polymerase chain reaction assay [20].
The DSMB provided study oversight. Safety reviews were per-
formed at the end of the ﬁrst phase, and after the 30th and
100th patients were recruited in phase 2.
Outcomes
This was an exploratory study focusing on safety, with the pri-
mary outcome deﬁned as a comparison of the proportion of pa-
tients with any AE, and with any SAEs, between the treatment
arms. The cutoffs described above for worsening hepatitis (ALT
>250 U/L) and myositis (CK >1000 U/L) deﬁned certain pre-
speciﬁed adverse events, but we also graded all laboratory ab-
normalities as grade 1–4 following the established Common
Terminology Criteria for Adverse Events system. Secondary
outcomes, as detailed in Supplementary Text 1, were as follows:
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(1) disease progression as deﬁned by admission to intensive care
unit, development of severe dengue (shock, severe bleeding, or
neurological involvement), or death; (2) fever clearance time;
(3) the area under the log10-transformed plasma viremia
curve between days 3 and 6 of illness; and (4) the lowest quality
of life score between days 2 and 6 of the study. Additional
Figure 1. Study enrollment and follow-up for phase 2 of the study. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; NS1,
dengue nonstructural protein 1.
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exploratory outcomes, intended primarily to evaluate vascular
leakage severity and other characteristic features of dengue,
are also described in Supplementary Text 1.
Statistical Analysis
The planned sample size of 300 patients in phase 2 was based on
medical and feasibility considerations as well as power consid-
erations for key endpoints. In a previous dengue trial performed
by our group, approximately 10% and 30% of participants expe-
rienced at least 1 SAE or AE, respectively [21]. The planned
sample size guaranteed a power of 80% to detect an increase
of 12% in the SAE frequency or 16% in the AE frequency.
More extensive power considerations are discussed in the pub-
lished protocol [19].
Cohort 1 was analyzed descriptively. The main analysis pop-
ulation included all patients in cohort 2 following the intention-
to-treat principle, with the principal analyses deﬁned a priori in
a written analysis plan. The proportion of patients with AEs was
compared between the treatment arms using Fisher exact test,
while the predeﬁned secondary endpoints were compared
based on linear regression for continuous endpoints, logistic
regression for binary endpoints, and Cox regression for time-
to-event endpoints. The main explanatory variable in the
regression models was the treatment assignment, and all analy-
ses were adjusted for day of illness at recruitment. Comparisons
of laboratory markers were additionally adjusted for the predose
enrollment value, and also for serotype and immune status for
plasma viremia comparisons.
All analyses were performed with the statistical software R
version 3.1.3 (R Foundation for Statistical Computing, Vienna,
Austria).
Table 1. Baseline Characteristics of the Patients in Phase 2 of the Study
Characteristic
Placebo
(n = 151)
80 mg Lovastatin
(n = 149)
Age, y 27 (21–33) 25 (21–34)
Sex
Male 66 (44%) 65 (44%)
Female 85 (56%) 84 (56%)
Temperature, °C 38.2 (37.7–38.5) 38.2 (37.7–38.5)
Hours from fever onset to first treatment dosea
0–23 8 (5%) 6 (4%)
24–47 45 (30%) 35 (23%)
48–71 79 (52%) 80 (54%)
72–77 19 (13%) 28 (19%)
DENV serotype
1 62 (41%) 53 (36%)
2 18 (12%) 15 (10%)
3 13 (9%) 15 (10%)
4 52 (34%) 64 (43%)
Negative 6 (4%) 2 (1%)
Immune status
Probable primary 35 (23%) 43 (29%)
Probable secondary 111 (74%) 96 (64%)
Inconclusive 5 (3%) 10 (7%)
Plasma viremia, log10 copies/mL 7.9 (7.1–8.9) 7.8 (6.9–8.6)
Hematocrit, % 41.8 (39.2–44.8) 41.0 (38.7–44.2)
Platelet count, ×109 cells/L 111 (90–140) 112 (89–149)
WBC, ×106/dL 3.2 (2.3–4.0) 3.1 (2.3–3.9)
AST, U/L 51 (36–79) 45 (32–72)
ALT, U/L 38 (25–67) 31 (23–60)
CK, U/L 95 (67–153) 92 (67–123)
Cholesterol, mmol/L 3.8 (3.3–4.3) 3.8 (3.2–4.3)
The summary statistic is the absolute count (%) for categorical variables and median
(interquartile range) for continuous variables. Data were complete except for 1 missing CK
and 1 missing cholesterol value in the lovastatin group, and 3 missing viremia at baseline in
the placebo group. Moreover, there were 8 patients with negative plasma viremia at
baseline, which were excluded from the viremia summary. Of note, dengue virus
serotype could be determined in 1 of these cases, based on subsequent plasma viremia
measurements.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine
kinase; DENV, dengue virus; WBC, white blood cell count.
a All patients presented within 72 hours of fever onset. Screening was completed within 4
hours (as per protocol) in all except 2 and 5 cases in the placebo and lovastatin arms,
respectively. In these cases, the first dose of the study drug was given after 5 hours (77
hours from fever onset).
Table 2. Primary Outcomes: Adverse Event Details
Adverse Event
Placebo
(n = 151)
80 mg Lovastatin
(n = 149)
P
Value
Clinical and/or prespecified laboratory AEs
Any 97 (64%) 82 (55%) .13
Abdominal pain 4 (3%) 5 (3%) .75
Diarrhea 39 (26%) 29 (19%) .22
Vomiting 27 (18%) 22 (15%) .53
Bleedinga 51 (34%) 38 (26%) .13
Muscle pain 7 (5%) 7 (5%) 1
Hepatitisb 14 (9%) 16 (11%) .70
Myositisc 1 (1%) 1 (1%) 1
Thrombocytopeniad 1 (1%) 1 (1%) 1
Serious AEs
Any 8 (5%) 4 (3%) .38
Diarrhea 1 (1%) 0 1
Hepatitisb 6 (4%) 3 (2%) .50
Thrombocytopeniad 1 (1%) 1 (1%) 1
Grade 3/4 laboratory AEs
Any 112 (74%) 110 (74%) 1
High ALT (>200 U/L [M] or 185
U/L [F])
65 (43%) 65 (44%) 1
High AST (>200 U/L [M] or 185
U/L [F])
65 (43%) 65 (44%) 1
High creatine kinase (>570 U/L) 9 (6%) 6 (4%) .60
Low platelet count (<50 × 109/L) 89 (59%) 84 (56%) .73
Low sodium (<120 mmol/L) 1 (1%) 0 1
Low white cell count
(<1 × 109/L)
1 (1%) 3 (2%) .37
Data are presented as No. (%) unless otherwise specified. P values derived from Fisher
exact test.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate
aminotransferase.
a Mild mucosal bleeding (eg, gum, nose, vaginal bleeding) in all cases. In 1 patient the
attending physician elected to administer a platelet transfusion as the platelet count was
15 × 109/L although the bleeding was not clinically severe.
b Hepatitis defined here as ALT >250 U/L.
c Myositis defined here as creatine kinase >1000 U/L.
d Thrombocytopenia defined as a platelet count that led to clinical concern. In these cases
the platelet nadir fell to <20 × 109/L and was slow to recover. Conventionally, in Vietnam
patients are kept in hospital until the platelet count is >50 × 109/L.
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RESULTS
Patients were recruited into phase 1 in November and Decem-
ber 2012 (the trial proﬁle is shown in Supplementary Figure 1).
The baseline characteristics were similar in the 2 study groups;
illness duration and AE rates were also comparable, and all AEs
resolved fully (Supplementary Tables 1 and 2).
Following the initial safety review by the DSMB, phase 2 ran
from April 2013 to January 2015. Figure 1 shows the trial pro-
ﬁle. Of the 515 subjects with a positive NS1 test who were as-
sessed for eligibility, 339 underwent formal screening and 300
patients were enrolled and randomized.
The baseline characteristics were similar between the 2 study
groups (Table 1). Treatment was stopped prematurely in 17 pla-
cebo and 19 lovastatin recipients. Eleven patients in the placebo
arm developed laboratory abnormalities on study day 3 where
the protocol mandated cessation of the study drug: 10 with
ALT elevations >250 U/L and 1 with a CK elevation >1000 U/L.
Twelve patients in the lovastatin arm had ALT elevations
>250 U/L that required the drug to be stopped. These abnor-
malities were not associated with clinical deterioration. The
study physicians elected to stop the study drug in 3 other
cases (1 placebo, 2 lovastatin) due to aspartate aminotransferase
elevations, although the ALT levels did not meet the stopping
criteria.
Treatment allocation was unblinded in 1 case (placebo arm),
where a pregnancy test requested by the patient on study day 6
was positive (the enrollment test was negative). Two patients in
the lovastatin arm withdrew from the study within 24 hours (1
self-discharged and 1 withdrew consent after the ﬁrst dose of
study drug); no AEs were documented in these cases. Data
from other participants who withdrew from the study later
are included in the analyses up to the time of withdrawal.
The number of AEs did not differ signiﬁcantly between the
groups (Table 2). Ninety-seven of 151 (64%) patients in the pla-
cebo group and 82 of 149 (55%) patients in the lovastatin group
had a clinical and/or prespeciﬁed laboratory AE (P = .13). Eight
patients in the placebo group and 4 patients in the lovastatin
group experienced an SAE (P = .38). One hundred twelve of
151 (74%) patients in the placebo group and 110 of 149
(75%) patients in the lovastatin group had at least 1 grade 3
or 4 laboratory AE identiﬁed (P = 1).
Biochemical evidence for hepatic dysfunction was common,
with similar proportions of participants (31/151 [21%] and 38/
149 [26%]) in the placebo and lovastatin groups, respectively,
exceeding the prespeciﬁed ALT cutoff of 250 U/L at some
time during the acute illness, in most cases after completion
of study drug (Supplementary Figure 3). Although thrombocy-
topenia was common, in no case did the platelet count drop to
<5 × 109/L; however, in 1 patient in each group the platelet re-
covery was slow, requiring inpatient monitoring for an addi-
tional 48 hours. Minor mucosal bleeding was also frequent in
both treatment arms. No participant in phase 2 experienced sig-
niﬁcant mucosal bleeding, but in 1 case the attending physician
elected to give a platelet transfusion, as the count was 15 × 109/L
when bleeding occurred. One patient in each group developed
clinical myositis with a CK >1000 U/L, although less marked
CK elevations were common.
The SAEs were all in the category of “prolonged hospitaliza-
tion.” In 11 patients these prolonged hospital stays were for
monitoring of abnormal laboratory tests (9 patients had hepa-
titis, plus the 2 cases with thrombocytopenia mentioned above)
without clinical symptoms, while in 1 placebo recipient the pro-
longed stay was for diarrhea and persistent fever. All SAEs re-
solved fully.
Two patients in the placebo group developed hypovolemic
shock, and 1 patient in the lovastatin group was admitted to in-
tensive care for close monitoring. The fever clearance time did
not differ signiﬁcantly between the study groups (Table 3 and
Supplementary Figure 2). Lovastatin had no observable effect
on dengue viremia kinetics overall, or on the quality of life
Table 3. Secondary Outcomes
Outcome Placebo (n = 151) 80 mg Lovastatin (n = 149) Comparison Estimate (95% CI); P Value
Disease progression OR of having disease progression:
Frequency, % 2/151 (1%) 1/147 (<1%) 0.53 (.02–5·57); P = .59
Time to fever clearance, d HR of time to fever clearance:
Median (IQR) 4 (3–5) 4 (3–5) 0.93 (.72–1.21); P = .60
AUC of viremia between days 3 and 6 of illness, log10 copies/mL × number of days
Median (IQR) 16.8 (12.5–21.6) 16.1 (11.5–20.2) Adjusted absolute mean difference:
Mean 16.9 16.2 −0.2 (−.9 to .5); P = .56
Minimum quality of life score between days 2 and 6 of study
Median (IQR) 50 (40–60) 50 (50–60) Adjusted absolute mean difference:
Mean 51 54 1 (−1 to 3); P = .38
Median (IQR) for time to fever clearance was based on Kaplan–Meier estimation.
Outcomes of 2 patients in the lovastatin arm were not available due to early withdrawal. In addition, 3 patients (1 in the lovastatin arm) were excluded from the analysis of fever clearance due to
having already defervesced at baseline; 11 patients (2 in the lovastatin arm) were excluded from the analysis of viremia as the initial dengue virus reverse transcription polymerase chain reaction
was negative or missing; and 4 patients (2 in the lovastatin arm) were excluded from the analysis of quality of life due to missing data.
Abbreviations: AUC, area under the log10-transformed plasma viremia curve; CI, confidence interval; HR, hazard ratio; IQR, interquartile range; OR, odds ratio.
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Figure 2. Viremia levels in lovastatin- and placebo-treated patients. Viremia is shown by serotype (A) and immune status (B). Values below the detection limit were imputed
by half of the serotype-specific detection limits. The colored lines in each graph correspond to loess scatterplot smoothers derived from local polynomial regression fitting to
data from each treatment arm. The gray background lines represent individual patient data. Overall, viremia kinetics did not differ significantly between the treatment groups.
Abbreviation: DENV, dengue virus.
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scores (Table 3). Post hoc subgroup analyses to investigate
potential effects by serotype and immune status suggested a
possible beneﬁt of lovastatin in dengue virus (DENV) type
2–infected participants for viremia AUC, and in secondary in-
fection for time to undetectable viremia (Figure 2 and Supple-
mentary Table 3). However, the corresponding overall tests for
treatment effect heterogeneity by serotype or immune status
did not reach signiﬁcance, and these subgroup analyses were
not predeﬁned. Thus, these results should be interpreted with
caution [22].
There were no signiﬁcant differences between the treatment
arms in the various predeﬁned exploratory endpoints (Table 4),
except in the peak percentage change in total cholesterol levels
relative to enrollment values; a greater relative reduction was ob-
served in the lovastatin group (30%) compared with the placebo
group (23%) (P < .0001; Supplementary Figure 4). Markers for
plasma leakage were similar between the treatment arms.
DISCUSSION
We hypothesized that the beneﬁts associated with statin use in
several observational studies of acute inﬂammatory syndromes
might be relevant to dengue, a condition in which endothelial
dysfunction is central to pathogenesis. In this randomized, dou-
ble-blind, placebo-controlled trial in Vietnamese adults with
dengue, we found that lovastatin was safe and well tolerated.
Speciﬁcally, we found no evidence of AEs on hepatic or muscle
dysfunction, both characteristic features of acute dengue as well
as recognized complications of statin therapy. However, we also
found no evidence of a beneﬁcial effect on any clinical or viro-
logical endpoints.
Although our study did not include pharmacokinetic analy-
sis, we used 80 mg lovastatin daily, and it is reasonable to as-
sume that therapeutic concentrations were achieved as
evidenced by the signiﬁcantly greater reduction in cholesterol
in the lovastatin group. The rates of clinical and laboratory
AEs were similar between the treatment arms. Rates of SAEs
were also similar, and in all cases these events were classiﬁed
as serious due to prolonged hospitalization for laboratory
monitoring rather than on the basis of clinical deterioration.
Biochemical abnormalities were observed frequently in both
treatment arms, and were no more prevalent in the lovastatin
arm.
Progression to severe dengue occurred infrequently in the
study population (1%) and there was no difference in the rate
of disease progression between the study groups. In view of
the small number of events, it is possible that the study missed
a small beneﬁcial effect. The frequency of dengue shock syn-
drome is higher in children and, hence, children are the pre-
ferred patient population for investigation of drugs with
endothelial stabilizing properties [23]. However, since we ob-
served no differences in the magnitude of hemoconcentration
or in the presence of effusions on ultrasound between the
Table 4. Exploratory Outcomes
Outcome Placebo (n = 151)
80 mg Lovastatin
(n = 149)
Comparison Estimate (95% CI);
P Value
Platelet nadir (between days 3 and 8 of illness), × 109 cells/L 43 (24–64) 44 (26–71) 2 (−4 to 9); P = .45
Peak hematocrit (between days 3 and 8 of illness), % 46.0 (42.8–49.3) 44.3 (42.0–49.0) −0.6 (−1.2 to .1); P = .10
Peak percentage change in hematocrit from baseline (between days 3
and 8 of illness), %
9.7 (4.5–15.2) 8.9 (5.0–12.7) −1.3 (−2.9 to .3); P = .11
Peak ALT (between day 3 and 8 of illness), U/L 110 (64–184) 89 (46–185) 6 (−28 to 40); P = .72
Peak ALT (during study), U/L 140 (82–222) 133 (67–269) 17 (−20 to 54); P = .37
Peak CK (between day 3 and 8 of illness), U/L 125 (80–199) 108 (70–200) 56 (−85 to 196); P = .44
Peak CK (during study), U/L 125 (80–199) 116 (72–200) 57 (−83 to 197); P = .43
Peak percentage change in cholesterol from baseline (between days 2
and 6 of study), %
−23.1 (−29.4 to −15.4) −30.4 (−38.4 to −23.6) −8.5 (−11.3 to −5.6); P≤ .0001
Peak viremia (between days 2 and 6 of study), log10 copies/mL 7.5 (6.4–8.7) 7.4 (6.5–8.5) 0.0 (−.2 to .2); P = .95
AUC of viremia between days 1 and 6 of study,
log10 copies/mL × days 26.2 (18.2–31.8) 22.7 (17.6–30.0) −0.6 (−1.7 to .5); P = .31
Undetectable viremia achieved 71/145 (49%) 87/147 (61%) 1.37 (.98–1.91); P = .06
Ascites on ultrasound between days 5 and 7 of illness 23/142 (16%) 17/137 (12%) 0.69 (.35–1.37); P = .29
Pleural effusion on ultrasound between days 5 and 7 of illness 14/142 (10%) 11/137 (8%) 0.79 (.34–1.81); P = .58
Colloid requirement 1/151 (0.66%) 0/147 (0%) NA
Total no. of days in hospital 8 (7–8) 8 (7–8) 0.0 (−.3 to .3); P = .89
Summary statistics are median (interquartile range) for continuous variables and frequency/No. (%) for categorical variables. The number of missing values was <8% in both arms for all
outcomes.
Estimates are absolute mean differences (for all continuous laboratory endpoints), odds ratios of having the event (for binary endpoints), or hazard ratio of time to undetectable viremia (for
undetectable viremia achieved). An estimate for colloid requirement was not available because there was only 1 case in the placebo group who required colloids.
All analyses were adjusted for day of illness at baseline. Analyses for continuous laboratory endpoints were also adjusted for the baseline value of the corresponding endpoint. Analyses for
plasma viremia (peak viremia, AUC of viremia, time to undetectable viremia) were additionally adjusted for dengue serotype and immune status.
Abbreviations: ALT, alanine aminotransferase; AUC, area under the log10-transformed plasma viremia curve; CI, confidence interval; CK, creatine kinase; NA, not applicable.
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study groups in this adult trial, we do not consider there to be a
compelling case for a trial of statin therapy in children at pre-
sent. We also found no other evidence of an anti-inﬂammatory
effect; in particular, fever clearance times were unaffected by
statin therapy.
Another limitation of our study is that we obtained sparse
data on DENV-2 and DENV-3 due to the dominance of
DENV-1 and DENV-4 during the study. Although in vitro lab-
oratory studies have suggested that statins may reduce dengue
virion assembly, we found no evidence of an antiviral effect
[14]. It is possible that the effects of statins may differ between
the serotypes and it is interesting to note that the work that sug-
gested a potential antiviral effect used DENV-2 [14–16].
As in other recent trials of antiviral and immunomodulatory
agents for dengue [21, 24–26], we administered the study drug
within 72 hours of illness onset. It is possible that even initiating
a therapeutic within this timeframe is too late to modulate the
disease pathways. Peak viremia typically occurs earlier in the
illness [27]. In addition, there is evidence that endothelial dys-
function is established by 72 hours [28]. To favorably modulate
outcome, earlier intervention may be necessary, which is a sig-
niﬁcant hurdle in many endemic regions as patients rarely pre-
sent to healthcare so early. It also raises the question of whether
therapeutic development should focus more on identifying che-
moprophylactic agents that could be used in those at most risk
of severe disease, and also on optimizing supportive care for
those who do develop severe disease. The ability to distinguish
patients at risk of severe disease early in the course of illness
could lead to a more targeted clinical trial approach. The use
of dengue human infection models may also allow streamlining
of potential therapeutic candidates [29].
Following the initial hope raised by observational studies sug-
gesting that prior statin therapy might improve outcomes in a
variety of inﬂammatory conditions, several prospective trials in-
vestigating statins as adjunctive therapy have recently been pub-
lished [12, 13, 30]; similar to our study ﬁndings, none of these
trials showed a beneﬁcial role for de novo statin therapy. Despite
these negative results, this “discovery-in-practice” approach re-
mains important given the high preclinical failure rate observed
with traditional drug discovery. A dengue therapeutic or che-
moprophylactic agent remains a desirable component of a
dengue control package and, given the ongoing expansion of
dengue’s geographic footprint, both drug development ap-
proaches need to be explored.
In conclusion, we have shown that lovastatin therapy is safe
in adult patients with dengue, although we did not demonstrate
a clinical or virological beneﬁt. Although the study ﬁndings do
not endorse adjunctive statin therapy for dengue, the data pro-
vide reassurance to clinicians about the safety of continuing sta-
tin therapy in patients who develop dengue. Early diagnosis and
recognition of severe features, together with good supportive
care, remain central to effective clinical management.
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materials are not copyedited and are the sole responsibility of the author, so
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